Ovid Therapeutics Inc. announced that it will receive $25,861,228 in a round of equity funding on January 6, 2017. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.055 USD | +1.44% |
|
+20.71% | -67.24% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.24% | 73.78M | |
+18.64% | 126B | |
+23.57% | 118B | |
+23.70% | 27.87B | |
-17.69% | 20.95B | |
-15.13% | 16.92B | |
-14.68% | 16.18B | |
+9.32% | 14.84B | |
-46.10% | 14.79B | |
+53.05% | 14.08B |
- Stock Market
- Equities
- OVID Stock
- News Ovid Therapeutics Inc.
- Ovid Therapeutics Inc. announced that it expects to receive $25.86 million in funding from Takeda Pharmaceutical Company Limited